Last updated: February 20, 2026
Lazertinib mesylate, a third-generation epidermal growth factor receptor (EGFR) inhibitor targeting resistant non-small cell lung cancer (NSCLC), is supplied mainly by several pharmaceutical manufacturers. These suppliers often focus on research and development (R&D) collaborations, clinical trial supply, and commercial manufacturing.
Key Manufacturers and Suppliers
1. Samsung Biologics / Samsung Bioepis
- Overview: Samsung Biologics has been involved in producing Lazertinib for the original developer, Yuhan Corporation. They have completed manufacturing for clinical trials and production-scale supplies.
- Role: Contract manufacturing organization (CMO).
- Production Capacity: Over 256,000 liters of biologics and small molecules capacity as of 2022.
- Supply Chain: Supplies Lazertinib for clinical and commercial use under licensing agreements with Yuhan.
2. Yuhan Corporation
- Overview: South Korea-based Yuhan developed Lazertinib. The company handles R&D, formulation, and licensing.
- Manufacturing: Collaborates with CMOs such as Samsung Biologics for production.
- Licensing: Holds licensing rights for Asia, with potential licensing or partnership agreements globally.
3. Third-Party CMOs and Contract Manufacturers
- Small-scale or specialty providers may assist with early-phase clinical supplies or formulation development.
- Common CMOs include WuXi AppTec, Boehringer Ingelheim, and Samsung BioLogics, depending on regional supply needs and phase of development.
4. Distribution Channels
- The drug is distributed through licensed pharmaceutical wholesalers following approval.
- As of 2023, Lazertinib has regulatory approval in South Korea and is in late-stage clinical development or awaiting registration in selected international markets.
Supply and Manufacturing Policies
- Manufacturing aligns with Good Manufacturing Practices (GMP).
- Supply chains have been streamlined through licensing agreements between Yuhan and CMOs.
- Licensing extends primarily to Asian markets; global distribution planned upon regulatory approvals.
Regulatory Approvals and Implications
- South Korea’s Ministry of Food and Drug Safety (MFDS) approved Lazertinib in 2021.
- Approval processes in the U.S., Europe, and other regions are ongoing or pending.
- Regulatory approvals directly influence supply volume and manufacturer involvement.
Summary of Key Suppliers
| Supplier |
Role |
Location |
Capacity/Notes |
| Samsung Biologics |
Contract manufacturer |
South Korea |
Large-scale biopharmaceutical manufacturing |
| Yuhan Corporation |
Developer & licensor |
South Korea |
R&D, formulation, licensing |
| WuXi AppTec |
Contract R&D and manufacturing |
China |
Early-phase supply |
| Other CMOs |
Clinical and specialized manufacturing |
Various |
Flexibility in supply chain operations |
Considerations for Investors and R&D Teams
- The concentration of manufacturing capacity in South Korea reduces geopolitical and supply chain risks.
- Contract manufacturing agreements specify capacity, quality standards, and supply timelines.
- Expansion into global markets depends on regulatory approvals, which may alter supplier dynamics.
Key Takeaways
- Lazertinib mesylate primarily supplied through partnerships between Yuhan Corporation and CMOs such as Samsung Biologics.
- Manufacturing capacity and licensing agreements determine supply volumes.
- Regulatory approvals influence distribution scope and additional supplier involvement.
- Global expansion depends on regulatory progress outside South Korea.
FAQs
Q1: Which companies are licensed to produce Lazertinib globally?
A: Yuhan Corporation is licensed primarily in South Korea. Other regions depend on licensing agreements, with CMOs like Samsung Biologics supporting manufacturing.
Q2: What stage of development is Lazertinib in?
A: Approved in South Korea (2021). It is in late-stage clinical development or registration processes in other territories.
Q3: How does manufacturing capacity impact supply?
A: Larger capacity firms like Samsung Biologics ensure steady supply for clinical and commercial needs but depend on licensing and contractual terms.
Q4: Are there alternative suppliers for Lazertinib?
A: Currently, supply is concentrated around Yuhan and its manufacturing partners; alternative suppliers may develop as global demand increases.
Q5: How might regulatory approval influence suppliers?
A: Approvals in new regions require establishing local manufacturing and licensing agreements, potentially expanding or shifting the supplier landscape.
References
[1] Yuhan Corporation. (2022). Lazertinib development and licensing. Yuhan Annual Report.
[2] Samsung Biologics. (2022). Manufacturing capabilities and strategic partnerships. Company Report.
[3] Korean Ministry of Food and Drug Safety. (2021). Lazertinib approval announcement.
[4] WuXi AppTec. (2023). Contract manufacturing services.
[5] European Medicines Agency. (2023). Clinical trial regulations and approval procedures.
